A self-represented James Mawhinney, the director of troubled Mayfair 101 director, has accused ASIC in court of misleading the judge in an ex-parte application brought in August that saw provisional liquidators appointed to the investment firm and Mawhinney banned from transferring assets out of Australia.
Race car driver and former owner of the famous Byron Bay Hotel, Max Twigg, misappropriated around $100 million in family trust money, taking steps to conceal the transfer of funds from his mother, a court has found.
A former University of Technology Sydney professor based in Shanghai has filed a lawsuit accusing the university of race and age discrimination, alleging his contract was not renewed after the dean of the business school said he wanted to appoint a Chinese person to his position.
Chevron has taken Australian petrol station operator Ampol to court over its allegedly infringing use of the ‘Caltex’ brand, eight months after the US oil giant severed the companies’ trade mark licence agreement.
A former executive of BlueScope Steel has pleaded guilty to obstructing an Australian Competition and Consumer Commission price fixing investigation, in the first criminal charges ever brought against an individual in relation to an ACCC probe.
Social media giant Facebook has come out swinging over the Morrison government’s proposed news media bargaining code, threatening to stop Australians from sharing local and international news on Facebook and Instagram if the code becomes law.
Financial services giant IOOF Holdings will be on the hook for any judgments or settlements reached in two class actions and an ASIC lawsuit as part of its $1.4 billion acquisition of NAB wealth management unit MLC.
Fintech firm iSignthis has revealed that it has spent over $1 million in legal costs pursuing its $264 million lawsuit over misleading and deceptive conduct against the Australian Stock Exchange.
The Federal Court has granted a bid by global solar cell manufacturer Hanwha to amend the patent behind its solar technology at the centre of a hotly contested infringement case against three rivals.
German pharmaceutical giant Boehringer has partially succeeded in its opposition to several vaccine patents filed by animal health company Zoetis, used to treat pneumonia in pigs.